Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

Sanofi Mulls Insmed Bid to Bolster Rare-disease Push

Published Nov 20, 2026
Share:
Summary:
  • Sanofi is evaluating a purchase of Insmed Inc., the rare-disease biotech valued around $32 billion, per a Thursday Bloomberg report.
  • After the report, Sanofi shares in Paris were up roughly 1.4% on Friday following a 2.9% slide the day before; Insmed jumped 21% in New York on Thursday.
  • CEO Belen Garijo, just over six months into the job, has been pruning projects, selling older drugs, and leaning into deals to shore up a thin pipeline and prepare for Dupixent's patent cliff.

Deal talk and the first market read

Bloomberg reported Thursday that Sanofi is weighing a bid for Bridgewater, New Jersey-based Insmed Inc., whose market value sits near $32 billion. Both companies declined to comment.

Traders moved quickly. Insmed surged 21% on Thursday in New York. Sanofi fell 2.9% on Thursday, then edged higher by about 1.4% on Friday in Paris.

Why this target lines up with the plan

Garijo arrived to muted investor enthusiasm, but she has pushed through visible changes: scrapping certain pipeline drugs, selling legacy products, and tilting resources toward what she calls more innovative assets. She moved fast to broaden the Dupixent partnership with Regeneron, unveiling the update alongside Manuela Buxo, who now leads specialty care at Sanofi, a pairing that eased what had been a tense, litigation-heavy relationship.

Buying Insmed would track with her emphasis on commercial firepower and rare diseases while giving Sanofi time to repair a spotty internal R&D record. "Insmed would be a good fit for Sanofi," said Markus Manns of Union Investment, adding that the CEO's job is to use acquisitions to blunt the pending loss of exclusivity for Dupixent and to strengthen the pipeline. "Both of these goals would be achieved with Insmed." BMO's Conor MacKay echoed the logic, citing "an attractive combination of demonstrated commercial execution and additional pipeline opportunities."

What Sanofi would be buying - and the risks

Insmed has two respiratory drugs on the market: Brinsupri for bronchiectasis and Arikayce for a chronic lung disease. The company is also developing a therapy intended for serious illnesses such as idiopathic pulmonary fibrosis and interstitial lung disease. Analysts say that could fit with Sanofi's respiratory expertise if a deal happens, and former Sanofi CEO Paul Hudson was recently appointed to Insmed's board.

But expectations have been reset. Before the takeover chatter, Insmed shares were down about 30% this year as two studies failed to show Brinsupri benefited patients with other conditions. While the initial rollout was strong, Insmed's internal costs have kept rising, and some investors question whether early sales strength reflected pent up demand.

When deal chatter surfaces, a clear daily note can save time, so sign up for the free Market Briefs

Price tag, firepower, and the CEO's M&A playbook

Sanofi's finance chief, François-Xavier Roger, has signaled the company has room to do a sizable deal. Using a customary 30% markup to the pre-announcement share price, Insmed would run about €31 billion, or $34 billion - a level Jefferies analyst Michael Leuchten said is "not entirely out of reach." Some investors and analysts warned the likely price could stretch Sanofi, and Claus Henrik Johansen of Global Health Invest said whether Sanofi can convert the assets into sales and pipeline progress will decide if the deal is "strategically sound and value-enhancing for the shareholders of Sanofi." His caution: "It's not a cheap acquisition, and it leaves room for Sanofi to prove that it is the right owner of these assets."

If it closes, the deal would be the largest global biopharma transaction since late 2023, when Pfizer agreed to acquire Seagen Inc. for $43 billion.

Garijo has leaned on deals before. At Merck KGaA, she worked through a post pandemic slowdown and two major drug setbacks by striking acquisitions, including SpringWorks Therapeutics for $3.9 billion, while a pending $11.3 billion purchase of Bio-Techne followed two months after she left. When she arrived at Sanofi, the pipeline she took over had unnerved investors after multiple trial failures pushed Paul Hudson to depart, despite steady growth from Dupixent.

She has yet to show she can fix Sanofi's internal development challenges, and newly appointed R&D head Paulo Fontoura, formerly of Roche, has not had time to lay out potential changes. The bottom line: investors are getting a clearer look this week at her willingness to use M&A to jump start a turnaround.

What it means for your portfolio: a Sanofi-Insmed deal would swap significant revenue potential and development risk under Sanofi's umbrella and refocus growth on respiratory and rare-disease assets. Watch for any formal announcement, guidance on financing, and how Brinsupri, Arikayce, and late-stage respiratory programs would slot into Sanofi's growth plan.

When headlines shift quickly, get the five minute rundown that explains markets simply by subscribing to Market Briefs newsletter

Disclosure

Recent News

1 2 3 … 132

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 17, 2026
Is the Stock Market Going to Crash? Why Nvidia and the Fed Have Investors on Edge
  • Tech stocks are selling off because investors don't know who will lead Nvidia, the company that has been funding the AI industry and selling it chips.
  • Inflation has the Federal Reserve planning to raise interest rates, with a hike expected in December, and that puts pressure on homebuyers, private equity and the $40 trillion national debt.
  • Briefs Finance CEO Jaspreet Singh says nobody has a crystal ball, so his rules are to buy when markets are low, hold long term and invest only what you're willing to lose.
Read More
November 16, 2026
The $40 Trillion National Debt: Trump's 4-Part Plan to Make It Feel Smaller
  • The national debt is above $40 trillion, and the Federal Reserve has gone from sending Washington its profits to losing money.
  • President Trump's four-part plan leans on shorter-term debt, stablecoin companies buying Treasuries, a bigger balance sheet and government stakes in private companies.
  • The goal is to outgrow the debt, not pay it off, so Jaspreet Singh points investors to the seven industries where Washington wants growth.
Read More
November 16, 2026
The Fed Is Talking About a Jumbo Interest Rate Hike. It Has No Easy Way Out
  • The Fed makes its next rate decision on December 9 and is now talking about jumbo interest rate hikes of 0.5%, though one in December looks unlikely.
  • Washington will pay a record $1.05 trillion in interest this year on $40 trillion of debt, and that debt resets at higher rates as the Fed hikes.
  • Jaspreet Singh's five moves are to pay down variable-rate debt, earn interest on your savings, know which stocks feel the pressure, look at value and hedge.
Read More
November 16, 2026
Buying on Margin Is at a Record High. Here's the Risk for the Stock Market
  • Margin debt, the money investors borrow to buy stocks, is at a record of around 4.6% of GDP, up from 3.9% in 2021.
  • ETF money has more than tripled in five years to 7% of GDP, while corporate buybacks and 401(k) money sit below their earlier peaks.
  • Margin calls and panic selling can make the next downturn deeper, so Jaspreet Singh keeps buying broad market funds and says most investors should skip margin debt.
Read More
November 16, 2026
Housing Prices Are Falling. Buying a House Still Isn't Cheaper
  • Housing prices have fallen for four straight weeks, but mortgage rates around 7.2% keep the monthly payment about where it was in 2023.
  • Talk of a jumbo Fed rate hike and a plan to sell Fannie Mae and Freddie Mac on the stock market could both push mortgage rates higher.
  • Briefs Finance CEO Jaspreet Singh treats a house as a liability: buy within your budget and let your investments build the wealth.
Read More
November 14, 2026
Nvidia News: Jensen Huang Is Out, and the "Bank" Behind American AI Just Lost Its Founder
  • Jensen Huang is out at Nvidia over affairs with multiple people, and the company he founded has been the bank of American AI, with about $30 billion into OpenAI and $10 billion into Anthropic.
  • A hotter-than-expected inflation report has Fed officials talking about a possible 0.5% hike in December, and gold, silver, and bitcoin fell on the news.
  • President Trump said the US may not need a deal with Iran, keeping oil prices and inflation risk high. Jaspreet Singh breaks down what it all means for AI stocks and your portfolio.
Read More
November 14, 2026
Record Highs, a 57-Year Low in Jobless Claims, and a Stock Market Bubble: Inside the Weirdest Market in History
  • Stocks are booming at the fastest pace in years, jobless claims just hit a 57-year low, and most investors still feel like nobody is hiring.
  • The Fed is protecting the dollar over the economy, oil swings on every Iran headline, and a few AI companies are carrying an S&P 500 where four of five stocks sit in a correction.
  • Jaspreet Singh explains why circular financing between Nvidia, OpenAI, Anthropic, and SpaceX rhymes with 2008's house of cards, and how his three investing pillars handle a stock market bubble.
Read More
November 14, 2026
Is a Recession Coming? The Fed Just Made a U-Turn It Has Only Made Twice in 60 Years
  • The Fed has raised rates, cut them, then raised them again only twice in the last 60 years, and both times the economy fell into a recession and stocks crashed.
  • The same stop-and-go cycle is playing out now, with one big difference: US debt is 125% of GDP today versus about 30% in 1980.
  • In the 1970s gold rose roughly 24x, real estate 157%, stocks lagged, and cash lost half its value. Jaspreet Singh lays out five assets to consider before the next flip.
Read More
November 14, 2026
The 2027 Tax Brackets Are Out: How Some Investors Can Earn $135,300 and Pay $0
  • The IRS 2027 tax plan keeps the same seven rates but widens every bracket and lifts the married-filing-jointly standard deduction to $33,200.
  • The 0% long-term capital gains bracket rises to $102,100, so a household living on $135,300 of investment income could owe $0 in federal income tax.
  • C corporations still pay 21%, small businesses keep the 20% QBI deduction, and the 401(k) limit climbs to $25,500 with an $8,500 catch-up for investors over 50.
Read More
November 14, 2026
Rare Earth Stocks: Why China's January 2027 Ban Could Be the Opportunity of the Decade
  • China plans to block rare earth exports to the US on January 10, 2027, and the US produces effectively zero of the 17 metals that go into phones, cars, dishwashers, and missiles.
  • When China cut off Japan in 2010 and squeezed Germany from 2015, some rare earth prices jumped 18x and 15x, and one rare earth company went bankrupt while another soared.
  • Washington is already putting billions into MP Materials, Vulcan, and a stockpile called Project Vault, and Jaspreet Singh walks through how investors can get exposure to rare earth stocks and ETFs.
Read More
1 2 3 … 33
Share via
Copy link